Asymmetry Capital Management

Our Team

Scott Kay, Founder & CIO

Scott Kay launched the Asymmetry Funds in 2013. He began his career at Pfizer Inc., then joined Banc of America Securities, LLC, where he covered major pharmaceuticals. He was promoted to Senior Global Pharmaceuticals Analyst and was ranked "Best Up and Comer" by Institutional Investor. In 2003, he joined Andor Capital Management, a diversified long/short equity hedge fund, covering specialty and large-cap pharmaceuticals. When Andor closed, he became a Founding Partner and the Therapeutic Sector Head at Partner Fund Management (PFM), a San Francisco-based long/short equity hedge fund. After 7 years at PFM, he left in 2011 to launch Asymmetry.

Scott received his B.S. in Marketing, with a finance concentration, from the State University of New York at Oswego.

Scott Kay

Chris Zellner

Chris Zellner, Founder, COO & CCO

Chris Zellner, joined Asymmetry in 2012. Chris has over 25 years of financial services experience and has worked for The New York Stock Exchange (NYSE), Morgan Stanley, Lehman Brothers, Merrill Lynch and Bank of America Merrill Lynch. He has a diverse background in financial services, having worked in Prime Brokerage, Equity Derivatives, and Equity Capital Markets. Chris also created the NYSE's IPO listing business.

Chris received his B.S. and M.B.A. from the Stern School of Business at New York University.


Alex Virgilio is the senior biotechnology/therapeutics analyst for the Asymmetry Global Healthcare Funds and a partner of Asymmetry Capital Management, L.P. Alex covers global biotechnology and therapeutics. Alex joined Asymmetry in October 2019.  Prior to Asymmetry, Alex had been a partner and analyst covering biotechnology stocks at Partner Fund Management, L.P. from 2007 to 2019.  Previously, he had been a Director of Corporate Development at Amgen (2003-2006), an Associate at Frazier Healthcare Partners (2002-2003), and a Senior Scientist at both Sunesis (1998-2000), and Amgen (1996-1998). 

Alex received an MBA from University of Michigan (2002), a Ph.D. in Chemistry from University of California at Berkeley (1996), and a B.S. in Chemistry from the Massachusetts Institute of Technology (1992).

Alex Virgilio

Zarak Khurshid

Zarak Khurshid, Analyst

Zarak Khurshid, joined Asymmetry in 2016. He covers all non-therapeutic healthcare sectors, which includes medical technology, devices, tools, diagnostics, labs, healthcare IT and services. Previously, Zarak worked as the Senior Vice President of Equity Research at Wedbush Securities PacGrowth Life Sciences, Caris & Company and as a Research Analyst at Pacific Growth Equities, LLC. He began his career in industry, working for Aurora Biosciences and Cytokinetics Inc.

Zarak received his B.A. in Economics and B.S. in Bioengineering from the University of California, San Diego.


Steven Grossenbacher is a biotechnology and therapeutics analyst for the Asymmetry Global Healthcare Funds. Steven joined Asymmetry in 2021. Prior to Asymmetry, Steven was an Analyst at PFM Health Sciences L.P. covering the public and private biotechnology sector (2018-2021). Previously, he was a Senior Analyst at Health Advances LLC (2017-2018). He has also served as an independent scientific consultant to early-stage private therapeutics companies.

Steven received his Ph.D. in Integrative Pathobiology (2017) and B.S. in Neurobiology, Physiology, and Behavior (2010) from the University of California at Davis.

Steven Grossenbacher

Michael Manifesto


Michael Manifesto, joined Asymmetry in 2014. He covers all healthcare sub-sectors. Michael worked as a Junior Analyst at Forward Management.

Michael received his B.S. in Business Administration, with a finance concentration, from California Polytechnic State University. Michael passed all three levels of the CFA exam on his first attempt.


William “Will” Fafinski is an associate analyst for the Asymmetry Global Healthcare Funds. Will supports the investment team across all healthcare sub-sectors. Will joined Asymmetry in November 2020. Prior to Asymmetry, William had been a Senior Associate at Craig-Hallum Capital Group (2018-2020) and was a research analyst at Barrington Capital Management, Inc. (2017-2018). 

Will received a B.A. in Finance from Texas Christian University (2017) and an M.S. in Finance from the University of Minnesota (2018). He is a CFA Level 3 candidate.

William “Will” Fafinski

Cindy Goldsmith, CFO


Cindy Goldsmith, CPA, joined Asymmetry in 2013. Previously, Cindy was the Manager of Hedge Fund Administration and Accounting Manager for Forward Management, and the Controller of Kensington Investment Group (acquired by Forward in 2009), where she was responsible for the accounting, taxes and administration of over 10 hedge funds. She was also a Manager at Kenneth Leventhal & Co, a certified public accounting firm.

Cindy received her B.S. in Accounting from the University of California, Berkeley.


Dorothy Tam is a senior associate of operations, finance, and marketing for the Asymmetry Global Healthcare Funds. Dorothy works closely with the firm’s COO and CFO to support the business operations of Asymmetry. Dorothy joined Asymmetry in March 2021. Prior to Asymmetry, Dorothy had been Project Manager at Sensato Investors where she worked across finance, compliance, marketing, and investor relations (2013-2020). She was also a Manager and Senior Analyst at Mellon Capital Management (2004-2013). 

Dorothy has a B.A. in Economics from the University of California at Berkeley (2013).

Dorothy Tam